Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135408
Status:
COMPLETED
Last Update Posted:
2016-09-28
First Post:
2005-08-25
Brief Title:
A Study of MDX-010 BMS-734016 Administered With or Without Prophylactic Oral Budesonide
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Randomized Double-Blind Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 BMS-734016 Administered With or Without Prophylactic Oral Budesonide Entocort EC in Patients With Previously Treated Unresectable Stage III or IV Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine Efficacy Safety and Tolerability of MDX-010 BMS-734016 administered with or without Prophylactic Oral Budesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None